Randomized equivalence trial of intensive and semiannual applications of fluoride varnish in the primary dentition.
For children in the primary dentition with high caries prevalence the standard semiannual application of fluoride varnish may not be successful in preventing tooth decay. Oftentimes this population is mobile and does not receive consistent preventive care. This trial tested whether an intensive fluoride 5% sodium varnish regimen (three applications/2 weeks) applied annually has an equivalent effect on caries progression in the primary dentition compared to single applications applied semiannually. This study was a randomized clinical trial with two treatment groups. All participants (n = 600; mean age +/- SD = 55.3 +/- 4.6 months) received three varnish applications (active varnish or placebo) at semiannual visits over 3 years. Once per year the intensive-treatment group received one set of three active treatments and three placebo treatments 6 months later, each time within 2 weeks. The standard group received one active and two placebo treatments every 6 months. Children were assessed clinically at baseline and 12, 24 and 36 months after the initiation of the study. The mean (SD) numbers of newly decayed primary tooth surfaces observed over 3 years were 9.8 (8.6) and 7.4 (7.7) in the intensive and standard groups, respectively. The adjusted rate ratio was 1.13 (95% CI = 0.94-1.37, p = 0.20). In conclusion, the trial failed to demonstrate clear evidence of a difference in efficacy. However, differences of up to 36% greater rates of caries in the intensive group could not be ruled out, thus equivalence of the treatments cannot be concluded.
Weinstein
P
P
Department of Dental Public Health Sciences, University of Washington, Seattle, WA, USA.
Spiekerman
C
C
Milgrom
P
P
D002327:Cariostatic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002675:Child, Preschool; D015331:Cohort Studies; D004245:DMF Index; D003731:Dental Caries / Q000517:prevention & control*; D003733:Dental Caries Susceptibility; D018450:Disease Progression; D005260:Female; D005460:Fluorides, Topical / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010919:Placebos; D016037:Single-Blind Method; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000493:pharmacokinetics; D013810:Therapeutic Equivalency; D013997:Time Factors; D014094:Tooth, Deciduous / Q000187:drug effects*; D016896:Treatment Outcome
D002327:Cariostatic Agents; D005460:Fluorides, Topical; D010919:Placebos; D012969:Sodium Fluoride